Stephen J. Haggarty, PhD

  • Lab Phone: 617-643-3201

Research Investigator Profile

Stephen J. Haggarty, PhD

Stephen J. Haggarty, PhD

  • Associate Professor of Neurology,
    Harvard Medical School
  • Associate in Neuroscience,
    Massachusetts General Hospital
  • Director, Chemical Neurobiology Laboratory,
    Center for Human Genetic Research

 

Research Description

Dr. Haggarty’s long-term goal is to understand how changes in brain chemistry influence the neural circuits underlying mood and memory and the relevance of these changes to the etiology and treatment of brain disease. His research program involves combining synthetic chemistry, neuroscience, and human genetics. Using this chemical genomic approach, members of his group invent new methods for finding small-molecule probes that target key components of the neurocircuitry, and then use these probes to selectively perturb neuronal network function at the molecular, cellular and circuit level. These studies entail three types of experiments:

  1. Small-Molecule Probes Targeting Epigenetic Mechanisms
  2. Generation & Characterization of Patient-Specific Stem Cell Models
  3. Functional Genomics & Biochemistry of Neuropsychiatric Disorders

Read more on the Haggarty Laboratory website at www.haggartylab.org/research

Research interests Neuropharamacology, neuroplasticity, neurotrophic factors, behavior, dopamine, chromatin remodeling, lithium, GSK-3 drug discovery, therapeutics, stem cells
Research techniques Chemistry, high-throughput screens, proteomics, gene expression profiling, molecular biology, chemical biology, imaging
Diseases studied Mood disorders, bipolar disorder, depression, schizophrenia, fragile X syndrome
Selected publications

NCBI PubMed link

  1. Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, Gale J, Zhao WN, Reis S, Barker DD, Berry-Scott E, Kim SW, Clore EL, Hooker JM, Holson EB, Haggarty SJ, Petryshen TL. A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. PLoS One. 2013 Aug 14;8(8):e71323.

  2. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia. 2013 Aug 5

  3. Haggarty SJ, Perlis RH. Translation: Screening for Novel Therapeutics With Disease-Relevant Cell Types Derived from Human Stem Cell Models. Biol Psychiatry. 2013 Jul 19. Review.

  4. Schroeder FA, Chonde DB, Riley MM, Moseley CK, Granda ML, Wilson CM, Wagner FF, Zhang YL, Gale J, Holson EB, Haggarty SJ, Hooker JM. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett. 2013 Jun 25.

E-mail address haggarty@chgr.mgh.harvard.edu
Lab mailing address Massachusetts General Hospital
Richard B. Simches Research Center/CPZN 5.412
185 Cambridge St
Boston MA 02114 

 

Updated 9/27/2013